A COMPARISON OF METHYLPHENIDATE FORMULATIONS IN THE TREATMENT OF ADHD

Main Article Content

Sarah E Shea

Keywords

METHYLPHENIDATE FORMULATIONS, ADHD

Abstract

This issue’s article by Margaret Steele et al1 reports   the   results   from   a   clinical   trial comparing  the  effectiveness  of  a  long  acting methylphenidate           formulation,  OROS- methylphenidate (OROS-MPH), with  immediate release  methylphenidate  (IR-MPH).

Abstract 605 | PDF Downloads 193

References

1. Steele M et al. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit –hyperactivity disorder. Can J Clin Pharmacol. Vol 13 (1) Winter 2006:e50-e62; Jan. 23, 2006.
2. Swanson J. Compliance with stimulants for attention-deficit/hyperactivity disorder: issues and approaches for improvement. CNS Drugs.2003;17(2): 117-31.
3. Sanchez RJ, Crimson ML, Barner JC, Bettinger T, Wilson JP. Assessment of adherence measures with different stimulants among children and
adolescents. Pharmacotherapy. 2005 Jul; 25(7):909-17.
4. Marcus SC, Wan GJ, Kemner JE, Olfson M. Continuity of methylphenidate treatment for attention deficit/hyperactivity disorder. Arch Pediatr Adolesc Med. 2005 Jun; 159(6): 572-8.
5. Dosreis S, ZitoJM, Safer DJ, et al. Parental perceptions and satisfaction with stimulant medication for attention deficit/hyperactivity disorder. J Dev Behav Pediatr. 2003 Jun;24(3): 155-62.